uniQure NV (QURE)
23.81
-0.82
(-3.33%)
USD |
NASDAQ |
Nov 13, 16:00
23.81
0.00 (0.00%)
After-Hours: 19:59
uniQure Enterprise Value : 1.564B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.564B |
| November 12, 2026 | 1.621B |
| November 11, 2026 | 1.618B |
| November 10, 2026 | 1.487B |
| November 09, 2026 | 1.492B |
| November 06, 2026 | 1.416B |
| November 05, 2026 | 1.368B |
| November 04, 2026 | 1.509B |
| November 03, 2026 | 1.568B |
| November 02, 2026 | 1.505B |
| October 30, 2026 | 1.635B |
| October 29, 2026 | 1.668B |
| October 28, 2026 | 1.645B |
| October 27, 2026 | 1.597B |
| October 26, 2026 | 1.412B |
| October 23, 2026 | 1.467B |
| October 22, 2026 | 1.515B |
| October 21, 2026 | 1.485B |
| October 20, 2026 | 1.487B |
| October 19, 2026 | 1.451B |
| October 16, 2026 | 1.422B |
| October 15, 2026 | 1.473B |
| October 14, 2026 | 1.365B |
| October 13, 2026 | 1.387B |
| October 12, 2026 | 1.426B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.478B |
| October 08, 2026 | 1.475B |
| October 07, 2026 | 1.517B |
| October 06, 2026 | 1.511B |
| October 05, 2026 | 1.493B |
| October 02, 2026 | 1.539B |
| October 01, 2026 | 1.533B |
| September 30, 2026 | 1.588B |
| September 29, 2026 | 1.441B |
| September 28, 2026 | 2.454B |
| September 25, 2026 | 2.393B |
| September 24, 2026 | 2.399B |
| September 23, 2026 | 2.707B |
| September 22, 2026 | 2.881B |
| September 21, 2026 | 2.814B |
| September 18, 2026 | 2.793B |
| September 17, 2026 | 2.799B |
| September 16, 2026 | 2.688B |
| September 15, 2026 | 2.730B |
| September 14, 2026 | 2.857B |
| September 11, 2026 | 2.828B |
| September 10, 2026 | 2.825B |
| September 09, 2026 | 2.931B |
| September 08, 2026 | 2.909B |
| September 04, 2026 | 2.827B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cartesian Therapeutics, Inc. | 130.96M |
| Moderna, Inc. | 89.30B |
| GRAIL, Inc. | 4.484B |
| Oncolytics Biotech, Inc. | 42.45M |
| Sangamo Therapeutics, Inc. | 40.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.22M |
| Revenue (Quarterly) | 5.196M |
| Total Expenses (Quarterly) | 66.41M |
| EPS Diluted (Quarterly) | -0.8758 |
| Gross Profit Margin (Quarterly) | -9.43% |
| Profit Margin (Quarterly) | -1.18K% |
| Earnings Yield | -14.90% |
| Normalized Earnings Yield | -14.80 |